BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 22550165)

  • 21. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic and clinico-pathologic analysis of metastatic uveal melanoma.
    Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R
    Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
    Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
    Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GNAQ and GNA11 mutations in uveal melanoma.
    Shoushtari AN; Carvajal RD
    Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic mutations in GNAQ occur early in uveal melanoma.
    Onken MD; Worley LA; Long MD; Duan S; Council ML; Bowcock AM; Harbour JW
    Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5230-4. PubMed ID: 18719078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Inhibition of Gα
    Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
    Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
    Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
    Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
    Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
    Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.
    Xu X; Wei WB; Li B; Gao F; Zhang Z; Jonas JB
    PLoS One; 2014; 9(10):e109699. PubMed ID: 25280020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
    Lietman CD; McKean M
    Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
    Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
    Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
    Turajlic S; Furney SJ; Stamp G; Rana S; Ricken G; Oduko Y; Saturno G; Springer C; Hayes A; Gore M; Larkin J; Marais R
    Ann Oncol; 2014 May; 25(5):959-67. PubMed ID: 24504448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uveal Melanoma:
    Psinakis F; Katseli A; Koutsandrea C; Frangia K; Florentin L; Apostolopoulou D; Dimakopoulou K; Papakonstantinou D; Georgopoulou E; Brouzas D
    Anticancer Res; 2017 Oct; 37(10):5719-5726. PubMed ID: 28982892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
    Van Raamsdonk CD; Bezrookove V; Green G; Bauer J; Gaugler L; O'Brien JM; Simpson EM; Barsh GS; Bastian BC
    Nature; 2009 Jan; 457(7229):599-602. PubMed ID: 19078957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.